Atheromatous plaques in diseased arteries typically contain inflammatory cells. Rupture of atheromatous plaque is thought to be the mechanism for acute myocardial infarction and acute coronary syndrome. The most common site of plaque rupture appears to be the shoulder region where inflammatory cells are most prominent. Thus the release of acute phase reactants as a response to inflammation have been proposed as a potential marker of an "unstable" atheromatous plaque and underlying atherosclerosis. Studies have shown a positive association between CRP and coronary artery disease. In a survey of 388 British men aged 50-69, the prevalence of coronary artery disease increased 1.5 fold for each doubling of CRP level (1). Multiple prospective studies demonstrated that baseline CRP is a good marker of future cardiovascular events (2). It has been suggested that CRP may be a good marker of cardiovascular risk in addition to lipid level.

Suitable for use in CRP immunoassay and immunoaffinity purification, and as coating/tracer antibody in ELISA. Other applications have not been tested.

ELISA: > 10e-6 (Titer) Optimal dilutions to be determined by the researcher.

Sp 2/0 myeloma cells with spleen cells from Balb/c mice.

Capture Antibody: C7907-09 Detection Antibody: C7907-04Q

May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Purified Human CRP

Supplied as a liquid in PBS, pH 7.4, 0.09% sodium azide.

Purified by Protein A affinity chromatography. Purity is tested by electrophoresis (> 90%).

Recognizes human CRP. Recognizes antigen both in the presence and in the absence (samples containing EDTA) of Ca2+.